Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> CH-223191 [301326-22-7]

CH-223191 [301326-22-7]

Imprimer Imprimer
Identifiez-vous

Référence HY-12684-5mg

Conditionnement : 5mg

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

CH-223191 is a potent and specific antagonist of aryl hydrocarbon receptor (AhR). CH-223191 inhibits TCDD-mediated nuclear translocation and DNA binding of AhR, and inhibits TCDD-induced luciferase activity with an IC50 of 0.03 μM[1].

In Vitro

CH-223191 (0.1-10 μM; pre-treated 1 hour) inhibits TCDD-caused cytochrome P450 1A1 mRNA expression in a in dose-dependent manner[1].
CH-223191 (0.1-10 μM; pre-treated 1 hour) causes a concentration-dependent inhibition of TCDD-induced cytochrome P450 enzyme activity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CH-223191 Related Antibodies

RT-PCR[1]

Cell Line: HepG2 cells
Concentration: 0.1-10 μM
Incubation Time: 1 hour
Result: Caused inhibition of TCDD-induced cytochrome P450 mRNA expression.

Western Blot Analysis[1]

Cell Line: HepG2 cells
Concentration: 0.1-10 μM
Incubation Time: 1 hour
Result: Decreased TCDD-caused cytochrome P450 1A1 protein Treatment.
In Vivo

CH-223191 (10 mg/kg; once a day; 25 days) suppresses cytochrome P450 1A1 expression and the intrahepatocyte fat content in liver, reduces activity of AST and ALT in TCDD-treated mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male ICR mice (6 weeks old)[1]
Dosage: 10 mg/kg
Administration: 10 mg/kg; once a day; 25 days
Result: Prevented TCDD-elicited cytochrome P450 induction, liver toxicity, and wasting syndrome in mice.
Masse moléculaire

333.39

Formule

C19H19N5O
CAS No.
Appearance

Solid

Color

Yellow to orange

SMILES

O=C(C1=CC=NN1C)NC2=CC=C(/N=N/C3=CC=CC=C3C)C=C2C
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Powder -20°C 3 years
4°C 2 years

*The compound is unstable in solutions, freshly prepared is recommended.

Solvant et solubilité
In Vitro: 

DMSO : ≥ 100 mg/mL (299.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9995 mL 14.9974 mL 29.9949 mL
5 mM 0.5999 mL 2.9995 mL 5.9990 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (3.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 2 mg/mL (6.00 mM); Suspended solution; Need ultrasonic
Pureté et documentation
Références

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
TQ0257-1mg
FICZ [172922-91-7]
 1mg 
T2448-5mg
CH-223191 [301326-22-7]
 5mg